(NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s respiratory syncytial virus (RSV) vaccine, for the prevention of lower ...

CAMBRIDGE, MA, USA I June 13, 2025 I Regor Therapeutics Group ("Regor"), a global innovator of clinical-stage biotechnology, today announced that it will ...

Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases ...

LONDON, UK I June 13, 2025 I AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.

Partnership further validates Ethris’ novel technology platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity ...

REDWOOD CITY, CA, USA I June 11, 2025 I Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics ...